Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Table 3 Laboratory samples to be collected during the trial

Sample	Day 1	Days 2–6	Day 7	Day 14
Blood samples	• Full blood count (3mL) • Urea and electrolytes, liver function tests, uric acid (7mL) • Serum for storage (10mL) Plasma base line pharmacokinetic samples (1X2 mL)		• Full blood count (3mL) • Urea and electrolytes, liver function tests, uric acid (7mL) • Serum for storage (10mL) • Plasma Pharmacokinetic samples (3×2mL)	• Full blood count (3mL) • Urea and electrolytes, liver function tests, uric acid (7mL) • Serum for storage (10mL)
Nasopharyngeal swab (only if COVID-19 testing not done yet)	• Diagnostic sample
Nose swab	Sample for viral load measurement/viral sequencing	Sample for viral load measurement/viral sequencing taken daily [self- sampled]	Sample for viral load measurement/viral sequencing
Stool samples			Sample for viral load measurement/viral sequencing	Sample for viral load measurement/viral sequencing

ISSN: 1745-6215